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Abstract: Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder related
to recurrent infections, as well as a range of non-infectious manifestations including autoimmune and
inflammatory disorders. We hypothesized that patients with CVID and different clinical phenotypes
would demonstrate alterations in lymphocyte T subsets, including T lymphocytes expressing programmed
cell death protein 1 (PD-1), and regulatory T lymphocytes. We performed flow cytometry in two CVID
groups: group 1 with infections only, and group 2 with infections and concomitant noninfectious man-
ifestations. Patients were 18–59 years old (mean 35.8 years of age). Increased proportions of CD8+PD-1+
T cells and reduced regulatory T cells were associated with lymphadenopathy. Amount of regulatory
T cells correlated with CD8+PD-1+ T lymphocytes (r = 0.54; p = 0.013), and with CRP (r = –0.64;
p = 0.004). Forty percent of patients expressed manifestations in addition to infections (group 2), and
they had reduction in number of regulatory T cells [8 (3–12) vs. 24 (11–26)/µl; p = 0.034), naive CD4+
T lymphocytes [36 (27–106) vs. 149 (81–283)/µl; p = 0.034], and elevated C-reactive protein (CRP) [5.33
(3.15–8.82) vs. 1 (1–2.16) mg/l; p = 0.003] in comparison to group 1. In conclusion, the amount of CD8+
T cells expressing PD-1 is associated with lymphadenopathy and number of regulatory T cells in patients
with CVID. Patients with CVID and non-infectious complications have increased level of inflammation
and alterations in regulatory T cells.
Keywords: common variable immunodeficiency, T cells, regulatory T cells, PD-1/PD-Ls, chronic
inflammation.
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Introduction
Common variable immunodeficiency disorder (CVID) is a primary immunodefi-
ciency, a rare disease highly diverse in clinical manifestations, and characterized by
hypogammaglobulinemia [1]. Although several monogenic forms of CVID have been
described, the mode of inheritance is mostly polygenic [1, 2]. Clinical manifestations
of CVID include primarily recurrent sinopulmonary infections, but patients may also
present increased predisposition to development of cancer, autoimmunity or inflam-
matory disorders [1]. Autoimmune disorders are diagnosed in about 20–25% of CVID
patients [3]. In a recent retrospective study of patients with PIDs by Fischer et al. [4],
survival time was significantly shorter in subjects with autoimmune and/or inflam-
matory manifestations than in patients without these manifestations. Moreover, in
that population the risk of autoimmune cytopenia was significantly higher in compar-
ison with general population. In addition, in Fischer’s report, inflammatory bowel
disease and arthritis were among the most frequent autoimmune/inflammatory dis-
eases and subjects with CVID and T-cell deficiencies demonstrated the highest risk
[4]. Various mechanisms of immune dysregulation, abnormalities in both B and
T lymphocytes leading to non-infectious complications in CVID have been proposed.
For instance, mutations in the gene encoding nuclear factor κB subunit 1 (NF-κB1),
reduced NF-κB1 protein levels, and expanded CD21low B-cell subset have been de-
monstrated in patients with CVID and inflammatory bowel disease, arthritis or Behçet
disease, compared with healthy controls subjects [5]. In addition, aberrations in
T lymphocytes, including decreased CD4+ lymphocytes, regulatory T cells, and
Th17 cells have also been suggested, and were associated with lymphoproliferative
complications in some studies [6–9]. To our best knowledge, the role of the pro-
grammed cell death protein 1 (PD-1) has not been extensively evaluated in CVID.
PD-1 exerts a suppressive effect on self-reactive T cells, and may also be engaged in the
suppression of effector T lymphocytes, and therefore may have negative effects on
antiviral and anticancer response [10–12]. The purpose of our research, therefore, was
to assess lymphocyte T subsets, including CD8+PD-1 and regulatory T lymphocytes in
CVID patients in relation to clinical manifestations.
Materials and Methods
The diagnosis of CVID was based on the European Society for Immunodeficiencies
(ESID) criteria [13]. We enrolled 20 adult patients with CVID receiving regular immu-
noglobulin replacement therapy every 3 to 4 weeks. Patients were included in the study
after informed written consent was obtained from each individual, the study was con-
ducted according to the approval by the local institutional ethics committee and in
accordance with the 1964 Helsinki declaration and its later amendments. None of the
patients received immunosuppressive therapy other than a low dose of glucocorticoids
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(less than or equal to 7.5 mg prednisone per day — 3 cases) at the time of the study and
in 6 months prior the study. Data such as number of infections, concomitant diseases, IG
dose, and age at diagnosis were collected retrospectively. Patients were divided into two
clinical phenotypes: group 1 including patients diagnosed with CVID, and with infec-
tions as a principal clinical manifestation, and group 2 including patients with CVID,
infections and associated inflammatory complications including gastrointestinal diseases
(inflammatory bowel disease, celiac disease, primary biliary cholangitis), psoriasis, psor-
iatic arthritis, and diabetes type 1. Additionally, patients in group 2 had clinical mani-
festations including splenomegaly, lymphadenopathy, and cytopenias.
Laboratory studies
All laboratory tests were performed on blood samples taken directly before consecu-
tive IG administration, and basic tests included: complete blood count with differen-
tial, glucose, creatinine, alanine aminotransferase (ALT), asparaginian aminotransfer-
ase (AST), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGTP),
bilirubin, thyrotropin releasing hormone (TSH), total protein, albumin, iron, ferritin,
total iron binding capacity (TIBC), IgG, IgA, IgM and C-reactive protein (CRP).
An abdominal ultrasound exam was also performed to evaluate spleen size.
Peripheral blood samples were incubated with monoclonal fluorescent-antibodies in
order to evaluate surface antigen expression among lymphocyte populations (including
anti-CD3-FITC, anti-CD4-Alexa Fluor 700, anti-CD8-APC-H7, anti-CD25-PE, anti-
CD27-BC510, anti-CD28-PerCP-Cy5.5, anti-CD127-BV605, anti-CD279-Alexa Fluor
647, anti-CD45RA-PE-Cy7, anti-HLA-DR-PerCP, anti-CCR7-BV421 obtained from
BD Biosciences, San Jose, CA, USA) using flow cytometry. The samples were then
treated with FACS Lysing Solution (BD), washed twice with PBS, handled in the
FACSCanto 10 color flow cytometer (Immunocytometry Systems, BD), and evaluated
with FACSDiva Software (BD). The absolute numbers of lymphocyte subpopulations
were determined applying dual-platform method. The absolute lymphocyte count was
derived from a hematology cell analyzer ABX Micros ES 60 Horiba (Horiba Medical,
Irvine, CA, USA). Lymphocytes were gated according to forward scatter (FSC) and side
scatter (SSC) signals from PBMC and T cells were gated according to CD3 expression.
Percentages and numbers of CD4 and CD8 positive subpopulations were assessed. T cell
subpopulations were also analysed for the presence of naïve (N) T lymphocytes
(CD45RA+CCR7+CD 28+CD27+CD127+CD279-), effector memory (EM) T cells
(CD45RA-CCR7-CD28+CD27+/-CD127+CD279+), central memory (CM) T cells
(CD45RA-CCR7+CD27++CD28++CD127++CD279-), terminally differentiated effector
memory (TEMRA) T cells (CD45RA+CCR7-CD 27-CD28-CD127+CD279+/-), activated
T cells (CD3/HLADR), and regulatory T cells (CD4+CD25++CD127-). PD-1 expression
(CD279) was assessed on CD4+ and CD8+ T lymphocytes.
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Statistical analyses
Results are presented as means (standard deviation, SD), medians (interquartile range,
IQR) for continuous variables, and percentages for categorical variables. The confor-
mity with a normal distribution was tested by the Kolmogorov–Smirnov test and
uniformity of variances by Leven’s test. Intergroup differences were calculated apply-
ing the unpaired 2-sided Student’s t-test or Mann–Whitney U test, and Fisher’s exact
test for continuous variables and proportions, respectively. Bivariate correlations be-
tween continuous variables were estimated by Spearman’s correlation coefficient (r).
All presented results were considered significant at p value below 0.05. Data were
analyzed with Statsoft Statistica® software (statsoft Inc., STATISTICA data analysis
software system, version 13).
Results
The amount of patients included in the study was 20, with 11 (55%) males; aged 18–59
years. Mean age of diagnosis of CVID was 27.5 ± 15.5 years, 7 patients were diagnosed
before 15 years of age. Immunoglobulins were administered intravenously in 17 pa-
tients and subcutaneously in 3 patients, with an average dose of 0.45 ± 0.13 g per
kilogram of body weight. Among 20 patients, 12 (60%) presented with infections only
(group 1), and 8 (40%) presented both with infections and other CVID associated
noninfectious conditions (group 2), i.e. there were 5 cases of gastrointestinal inflam-
matory diseases, 1 case of primary biliary cholangitis, 1 case of diabetes type 1, and
1 case of psoriatic arthritis. Additionally, in group 2 any cytopenia was found in 8 sub-
jects, lymphadenopathy and splenomegaly in 5 and 11 patients, respectively. Basic
clinical findings are presented in Table 1 and Table 2. Patients from group 2 had
significantly lower IgG serum levels despite comparable monthly IG dose, and elevated
CRP levels as well as higher ALT and ALP levels compared with group 1.








Age (years) 33.5 ± 13.1 39.1 ± 12.3 0.35
Age at CVID diagnosis (years) 25.6 ± 15.7 30.4 ± 15.9 0.51
Female sex (%) 50 37.5 0.67
Ig dose (g/kg) 0.41 ± 0.11 0.53 ± 0.14 0.05
IgG at diagnosis (g/l) 3.85 (1.44–5.24) 1.03 (0.37–2.8) 0.14
IgG (g/l) 8.00 ± 1.30 5.80 ± 1.50 0.003
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The results of the analysis of T lymphocyte subsets are presented in Table 3.
White blood cell count and lymphocyte count were comparable in both groups. Within
T lymphocytes, the number of naive CD4 T cells (median 447 cells/µl) and regulatory
T cells (median 8 cells/µl) were substantially lower in group 2 in comparison to group 1
(median 679 cells/µl; p = 0.034 and 24 cells/µl; p = 0.034), respectively. Remaining
T lymphocyte subsets, including numbers of T cells expressing PD-1 were comparable
in both groups (Fig. 1).
IgA (g/l) 0.24 (0.24–0.25) 0.25 (0.24–0.22) 0.65
IgM (g/l) 0.28 (0.17–0.59) 0.17 (0.17–0.27) 0.34
Data are shown as the means ± SD or the medians and the (25th and 75th) percentiles.








CRP (mg/l) 1 (1–2.16) 5.33 (3.15–8.82) 0.003
Leukocytes (109/L) 5.87 ± 1.88 8.5 ± 4.53 0.23
Erythrocytes (1012/L) 5.02 ± 0.44 4.8 ± 0.6 0.27
Haemoglobin (g/L) 138 ± 17 136 ± 18 0.71
Hematocrit (L/L) 0.41 ± 0.04 0.40 ± 0.04 0.51
Platelets (109/L) 210.5 ± 69.8 216.4 ± 153.4 0.48
Neutrophils (109/L) 3.07 ± 1.2 5.14 ± 2.91 0.09
Lymphocytes (109/L) 1.95 ± 0.8 2.45 ± 2.22 1
Monocytes (109/L) 0.63 ± 0.27 0.76 ± 0.5 0.77
AST (U/l) 25 (17–32) 29.5 (24.5–38.5) 0.25
ALT (U/l) 16 (13–29) 35 (32.5–51) 0.015
LDH (U/l) 358 ± 112.3 422.9 ± 140.2 0.17
GGTP (U/l) 11.5 (10–28) 21 (16–31) 0.30
ALP (U/l) 80.3 117.88 0.037
Glucose (mmol/l) 4.47 ± 0.63 5.2 ± 1.46 0.40
TSH (uIU/ml) 2.36 ± 1.09 2.25 ± 1.16 1
Creatinine (µmol/l) 64.7 ± 11.6 74.5 ± 34.5 0.79
CK (U/l) 112 (90–159) 64 (48–173) 0.24
Data are shown as the means ± SD or the medians and the (25th and 75th) percentiles.
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Splenomegaly was related to increased percentage of CD4+ lymphocytes (49.5 ±
10.2 vs. 34.5 ± 11.8%; p = 0.007) and reduced percentage of CD8+ lymphocytes
(median 36.5 vs. 50.1%; p = 0.008). Lymphadenopathy, was related to elevated CRP
level (median 7.02 vs. 1.62 mg/l; p = 0.02), lower percentage of naïve CD4+ T cells
(median 2.2 vs. 11.6%; p = 0.003), central memory CD4+ lymphocytes (median 4.6 vs.
9.2%; p = 0.003), higher proportion of CD8+ cells (66.4 ± 14.7 vs. 40.9 ± 9.0%;
p <0.001), elevated percentage of CD8+ lymphocytes expressing PD-1 (median 24
vs.14.1%; p = 0.001), and diminished proportion of regulatory T cells (0.5 vs. 1.2%;
p = 0.009) (Fig. 2). Malignancy was confirmed in 1 patient (non-melanoma skin
cancer). In the entire group of CVID patients, regulatory T cell number correlated
negatively with CRP (r = –0,64; p = 0.004), and was positively associated with counts
of CD8+PD-1+ T lymphocytes (r = 0.54; p = 0.013), and CD4+ naive T cells (r = 0.73;
p <0.001) (Fig. 3).








Lymphocytes (/µl) 1850 (1300–2300) 1660 (1000–3250) 0.88
CD4 (/µl) 679 (409–906) 447 (314–881) 0.33
CD4 naive (/µl) 149 (81–283) 36 (27–106) 0.03
CD4 central memory (/µl) 110 (83–138) 80 (49–144) 0.46
CD4 effector memory (/µl) 63 ± 45 94 ± 72 0.30
CD4 TEMRA (/µl) 0.4 (0.1–4) 2 (0.2–9) 0.79
Regulatory T cells (/µl) 24 (11–26) 8 (3–12) 0.03
CD4 PD-1 (/µl) 240 ± 147 254 ± 117 0.82
CD8 (/µl) 613 (371–869) 952 (264–1553) 0.56
CD8 naive (/µl) 124 (56–160) 43 (11–119) 0.15
CD8 central memory (/µl) 30 (18–50) 26.8 (10.4–48.1) 0.96
CD8 effector memory (/µl) 17.8 (0.5–51.4) 20 (7–34) 0.91
CD8 TEMRA (/µl) 12 (6–20) 20 (7–26) 0.56
CD8 PD-1(/µl) 205 (133–341) 320 (133–341) 0.56
Data are shown as the means ± SD or the medians and the (25th and 75th) percentiles.
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Fig. 1. Comparison of T cells and subsets in two groups of CVID patients with non-infectious
complications and infections-only. Representative plots with cells obtained from a CVID patient with
disease associated complications (left panel a and b), and a CVID patient with infections only (right panel
a and b) showing decreased number of regulatory T (Treg) cells (a), and naive CD4+ T cells (b),
comparable numbers of CD4+, CD8+ and CD8+ PD-1+ T cells (c–e). Horizontal lines represent the
medians. *p <0.05.
Fig. 2. Lymphadenopathy in CVID was associated with decreased percentage of regulatory T cells, naïve
CD4+ T cells and increased proportion of CD8+PD-1+ expressing T cells. Horizontal lines represent the
medians. **p <0.01, ***p <0.001.
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Discussion
We have demonstrated the positive correlation among the number of CD8+ T lym-
phocytes with PD-1 expression and regulatory T lymphocytes. We did not observe any
substantial differences in PD-1 expression on T cell subsets between the infection-only
group and the group with noninfectious complications, nonetheless we demonstrated
that patients with lymphadenopathy had nearly 1.5 times increased proportion of
CD8+ T cells expressing PD-1 in comparison with patients without lymphadenopathy.
Our research is one of a very small number of studies evaluating PD-1 expression on
T cells in CVID. We believe that this is the first work, that shows presence of relation
between regulatory T lymphocytes and CD8+ lymphocytes expressing PD-1 in CVID.
We have also demonstrated decreased counts of regulatory T lymphocytes and naive
CD4+ T lymphocytes, as well as increased C-reactive protein serum level in patients
with CVID and concomitant noninfectious complications in comparison to the in-
fection-only group. In addition, we showed that in the pooled groups low regulatory
T lymphocytes correlated with increased C-reactive protein level.
The PD-1/PD-L pathway regulates peripheral tolerance and it is involved in tumor
immunity and chronic infections [11, 12]. Our results are consistent with findings of
Kuntz et al., who found that CD8+ T lymphocytes of patients with CVID demon-
strated more antigen experienced and activated differentiation state, especially in
a group with lymphadenopathy and granulomatous disease [14]. It has been con-
firmed that in chronic infections PD-1 could be used as a marker of exhausted
CD8+ T cells with impaired function [15], but CD8+PD-1+ T cells are also found in
healthy humans where PD-1 is a marker of the majority of effector memory T cells
[16]. The mechanism of T cells exhaustion in CVID is not determined, but it may be
related to chronic activation of CD8+ T lymphocytes and prolonged expression of
PD 1 caused by recurrent infections [17]. Marashi et al. found increased proportion of
CMV CD8+ T lymphocytes in CVID patients, and high levels of interferon-γ and
tumor necrosis factor-α, compared with healthy controls [18]. Autoimmunity may
theoretically contribute to an excessive T cell response in CVID as well, although the
role of autoimmunity is unproven [17]. The role of PD-1 in T lymphocyte impairment
Fig. 3. Reduced number of regulatory T cells in CVID correlated with decreased number of CD8+PD-1+ T
cells (a); p <0.05, naive CD4+ T cells (b); p <0.001, and elevated C-reactive protein.
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has been studied in human with rheumatoid arthritis, ankylosing spondylitis, systemic
lupus erythematosus, myasthenia gravis or chronic hepatitis C infection [19–25]. In
chronic inflammatory diseases, chronic stimulation of CD8+ T cell could initiate
exhaustion similar to that observed in chronic infections [25]. Nevertheless, a study
by Petrelli et al. demonstrated that CD8+ PD-1+ lymphocytes in synovia of patients
with juvenile idiopathic arthritis were effector lymphocytes and were not exhausted
cells [26]. Therefore, according to these authors, PD-1+ CD8+ T cells could be antigen
experienced lymphocytes specific to certain sites of chronic inflammation. Data on
PD-1 in CVID is scarce. De Lollo et al. found enlarged expression of PD-1 on effector
memory CD4+ T lymphocytes compared to healthy individuals, but not on CD8+
lymphocytes [27]. Another study demonstrated, that in CVID the functional impair-
ment of CD4+ T cells was caused by PD-1 associated cell exhaustion, and in vitro CD4
proliferation was brought back by blocking PD-L1/2 [28]. Noteworthy finding of our
study is the association of CD8+ lymphocytes expressing PD-1 with regulatory T cells
in CVID. As regulatory T lymphocytes produce inhibitory cytokines such as inter-
leukin-10 or transforming growth factor β, they may contribute to CD8+ T lympho-
cyte exhaustion [29]. Furthermore, reduction of regulatory T cells and blockade of
PD-1 has common effect on reversal of exhaustion of CD8+ T cells [30]. Therefore,
decreased expression of PD-1 in CVID, resulting in increased T cell proliferation and
cytokine production may well impair immune responses and hasten autoimmunity,
which is associated with decreased regulatory T cells.
The finding of decreased regulatory T cells in CVID is in line with the previously
published data [31–33]. Observed changes in regulatory T cells in CVID may repre-
sent abnormal immune effects responsible for the phenomenon of autoimmunity [34].
Most of the studies evaluating the number and mechanisms of modulation of regu-
latory T cells function during inflammation refer to chronic inflammatory diseases,
which also may occur in the course of CVID. The exception was a study by Fevang
et al. performed in CVID patients, who showed that serum level of neopterin was
correlated negatively with the amount of regulatory T cells [32]. A study by van
Amelsfort et al. reported that the number of peripheral CD4+CD25++ regulatory T
lymphocytes in patients with rheumatoid arthritis was decreased as compared with the
level found in their synovial fluid [35]. That phenomenon may be associated with the
accumulation of regulatory T cells in tissues, and however not formally proven, it
might be also relevant to the results of our study. The function of regulatory T cells
may be varied in chronic inflammation, where impaired regulatory lymphocytes
might contribute to activation of immune response and predispose to autoimmunity,
as has been shown by Hguyen et al. [36].
We also found, that subjects with CVID and noninfectious complications pre-
sented additional T cell abnormalities, including decrease in naive CD4+ T lympho-
cytes. The decline in naive CD4+ T lymphocytes in CVID has been already described,
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and it was shown to be associated with the severity of disease [37, 38], and with
gastrointestinal symptoms or polyclonal lymphoproliferation [38]. Giovannetti et al.
have previously classified CVID patients according to number of naive CD4+ T lym-
phocytes, and the group with decreased number was characterized by T lymphocyte
activation, proliferation, apoptosis, and splenomegaly [37]. In our study lymphadeno-
pathy and low regulatory T cell number, but not splenomegaly, were related to lower
level of naive CD4+ lymphocytes.
A number of limitations of the study should be acknowledged. Firstly, the results
are limited by the small size and heterogeneity of the studied cohort of CVID patients
with various clinical manifestations, and patients were not analyzed for monogenic
defects associated with CVID. In addition, assessment of the immunological profile
in the peripheral blood may not represent the mechanisms generating and sustaining
organ-specific chronic inflammation. Furthermore, treatment with low dose of gluco-
corticoids in some patients, might have had an influence on studied lymphocyte subsets.
Conclusions
Our findings indicate that the amount of CD8+ T cells expressing PD-1 is associated
with lymphadenopathy and number of regulatory T cells in patients with CVID.
Additionally, patients with non-infectious, inflammatory complications have reduced
number of peripheral regulatory T cells, depletion of naive CD4+ T lymphocytes, and
higher level of inflammation. Although the implication of our findings for pathogen-
esis of CVID associated noninfectious complications is not clear, it emphasizes the
complexity of immune dysregulation associated with CVID. Additional studies are
needed to verify whether regulatory T lymphocytes and PD-1 expression abnormal-
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